

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)***

FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center
The Great Room (Rm. 1503), Silver Spring, Maryland

November 1, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Kalyani Bhatt, BS, MS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Walter S. Dunn, MD, PhD

Staff Psychiatrist and Assistant Clinical Professor
West Los Angeles Veterans Administration
Medical Center
University of California Los Angeles
Department of Psychiatry
Los Angeles, California

Jess G. Fiedorowicz, MD, PhD

Associate Professor
Departments of Psychiatry, Epidemiology and Internal
Medicine
University of Iowa Carver College of Medicine
Iowa City, Iowa

Satish Iyengar, PhD

Chair and Professor of Statistics
Department of Statistics
University of Pittsburgh
Pittsburgh, Pennsylvania

Felipe A. Jain, MD

Assistant Professor of Psychiatry
Department of Psychiatry
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Rajesh Narendran, MD

(Chairperson)
Attending Psychiatrist
Re:solve Crisis Network
Western Psychiatric Institute and Clinics
Associate Professor in Radiology and Psychiatry
Psychiatric Molecular Imaging Program
University of Pittsburgh
Pittsburgh, Pennsylvania

Kim O. Witzak

(Consumer Representative)
Co-Founder, Executive Director
Woodymatters
Minneapolis, Minnesota

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)***
November 1, 2018

MEETING ROSTER (cont.)

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Robert R. Conley, MD

(Industry Representative)

Global Development Leader
Pain and Core Therapeutic
Team and Distinguished Scholar
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana

DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS (Voting)

Kelly Besco, PharmD, FISMP, CPPS

Health-System Medication Safety Officer
OhioHealth Pharmacy Services
Dublin, Ohio

Marie R. Griffin, MD, MPH

Professor, Health Policy and Medicine
Director, Vanderbilt MPH Program
Department of Health Policy
Vanderbilt University Medical Center
Nashville, Tennessee

Laurel A. Habel, MPH, PhD

Associate Director, Cancer Research
Division of Research
Kaiser Permanente Northern California
Oakland, California

Sonia Hernandez-Diaz, MD, MPH, DrPH

Professor of Epidemiology
Department of Epidemiology
Harvard T.H. Chan School of Public Health
Boston, Massachusetts

Martin Kulldorff, PhD

Professor of Medicine and Biostatistician
Division of Pharmacoepidemiology and
Pharmacoeconomics
Department of Medicine
Harvard Medical School and Brigham & Women's
Hospital
Boston, Massachusetts

Steven B. Meisel, PharmD

System Director of Patient Safety
Fairview Health Services
Minneapolis, Minnesota

Anne-Michelle Ruha, MD, FACMT

Director, Medical Toxicology Fellowship Program
Department of Medical Toxicology
Banner University Medical Center
Clinical Associate Professor of Emergency
Medicine
University of Arizona College of Medicine
Phoenix, Arizona

Terri L. Warholak, PhD, RPh, CPHQ, FAPhA

Professor and Assistant Dean
Academic Affairs and Assessment
College of Pharmacy
University of Arizona
Tucson, Arizona

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)***

November 1, 2018

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Jane B. Acri, PhD

Chief, Medication Discovery & Toxicology
Branch
Division of Therapeutics and Medical
Consequences
National Institute on Drug Abuse
National Institutes of Health (NIH)
Bethesda, Maryland

David Cella, PhD

Professor Chairperson
Medical Social Sciences
Northwestern University Feinberg School of
Medicine
Chicago, Illinois

Stephanie Y. Crawford, PhD, MPH

Department of Pharmacy Systems
Outcomes and Policy
University of Chicago
Chicago, Illinois

Harriet de Wit, PhD

Department of Psychiatry and Behavioral
Neuroscience
The University of Chicago
Chicago, Illinois

Kathryn E. Flynn, PhD

Associate Professor of Medicine
Division of Hematology and Oncology
Senior Scientific Director for Patient-Reported
Outcomes
Center for International Blood & Marrow
Transplant Research
Milwaukee, Wisconsin

Roxanne E. Jensen, PhD

Program Director
Outcomes Research Branch
Health Care Delivery Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute, NIH
Bethesda, Maryland

Elizabeth Joniak-Grant, PhD

(Patient Representative)
Holly Springs, North Carolina

Brandon D.L. Marshall, PhD

Associate Professor
Department of Epidemiology
Brown University School of Public Health
Providence, Rhode Island

William T. Riley, PhD

Director
Office of Behavioral and Social Sciences Research
NIH
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management Advisory Committee Meeting (DSaRM)*
November 1, 2018

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Robert Temple, MD

Deputy Director for Clinical Science
CDER, FDA
Deputy Director (Acting)
Office of Drug Evaluation I (ODE I)
Office of New Drugs (OND), CDER, FDA

Mitchell Mathis, MD

Division Director
Division of Psychiatry Products (DPP)
ODE I, OND, CDER, FDA

Tiffany Farchione, MD

Deputy Director
DPP, ODE I, OND, CDER, FDA

Daniel J. Lee, MD

Clinical Reviewer
DPP, ODE I, OND, CDER, FDA

Ellis Unger, MD

Director
ODE I, OND, CDER, FDA

Judy Staffa, PhD, RPh

Director
Division of Epidemiology II (DEPI-II)
Office of Pharmacovigilance and Epidemiology
Office of Surveillance and Epidemiology
CDER, FDA

Dominic Chiapperino, PhD

Director
Controlled Substance Staff
Office of the Center Director, CDER, FDA

Semhar Ogbagaber, PhD

Statistician
Division of Biometrics I
Office of Biostatistics
Office of Translational Sciences, CDER, FDA